{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=NewAmsterdam+Pharma",
    "query": {
      "sponsor": "NewAmsterdam Pharma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=NewAmsterdam+Pharma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T09:06:25.056Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06982508",
      "title": "Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Antioxidant Absorption"
      ],
      "interventions": [
        {
          "name": "Obicetrapib 10mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-09-09",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-04T09:06:25.056Z",
      "location_count": 1,
      "location_summary": "Miami Gardens, Florida",
      "locations": [
        {
          "city": "Miami Gardens",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06982508"
    },
    {
      "nct_id": "NCT07794670",
      "title": "Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Preclinical Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Obicetrapib 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 400,
      "start_date": "2026-09",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-04T09:06:25.056Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07794670"
    },
    {
      "nct_id": "NCT05202509",
      "title": "Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atherosclerotic Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Obicetrapib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9541,
      "start_date": "2022-02-07",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2024-06-04",
      "last_synced_at": "2026-10-04T09:06:25.056Z",
      "location_count": 199,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 161 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05202509"
    },
    {
      "nct_id": "NCT05425745",
      "title": "Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemias",
        "High Cholesterol",
        "Hypercholesterolemia",
        "Familial Hypercholesterolemia",
        "Lipid Metabolism Disorder",
        "Metabolic Disease",
        "Lipid Metabolism, Inborn Errors",
        "Genetic Disease, Inborn",
        "Hyperlipoproteinemias"
      ],
      "interventions": [
        {
          "name": "Obicetrapib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 354,
      "start_date": "2022-07-25",
      "completion_date": "2024-05-28",
      "has_results": true,
      "last_update_posted_date": "2025-06-11",
      "last_synced_at": "2026-10-04T09:06:25.056Z",
      "location_count": 20,
      "location_summary": "Jonesboro, Arkansas • Toluca Lake, California • Sarasota, Florida + 17 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Toluca Lake",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05425745"
    },
    {
      "nct_id": "NCT06496243",
      "title": "Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemias"
      ],
      "interventions": [
        {
          "name": "obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 69,
      "start_date": "2024-12-02",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-10-04T09:06:25.056Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06496243"
    },
    {
      "nct_id": "NCT04753606",
      "title": "Randomized Study of Obicetrapib as an Adjunct to Statin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemias",
        "High Cholesterol",
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Obicetrapib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 120,
      "start_date": "2021-02-18",
      "completion_date": "2021-08-30",
      "has_results": true,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-10-04T09:06:25.056Z",
      "location_count": 19,
      "location_summary": "Anniston, Alabama • Huntington Park, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04753606"
    },
    {
      "nct_id": "NCT06305559",
      "title": "A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lipidemia",
        "Coronary Artery Disease",
        "Plaque, Atherosclerotic"
      ],
      "interventions": [
        {
          "name": "obicetrapib 10 mg + ezetimibe 10 mg FDC daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2024-05-16",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-10-04T09:06:25.056Z",
      "location_count": 1,
      "location_summary": "Hialeah, Florida",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305559"
    },
    {
      "nct_id": "NCT07219602",
      "title": "A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lipidemia",
        "Type 2 Diabetes (T2DM)",
        "Metabolic Syndrome (MetS)"
      ],
      "interventions": [
        {
          "name": "obicetrapib 10 mg + ezetimibe 10 mg FDC daily",
          "type": "DRUG"
        },
        {
          "name": "Obicetrapib 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2025-12-11",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-04T09:06:25.056Z",
      "location_count": 32,
      "location_summary": "Sun City West, Arizona • La Jolla, California • Pomona, California + 24 more",
      "locations": [
        {
          "city": "Sun City West",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Pomona",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219602"
    },
    {
      "nct_id": "NCT05142722",
      "title": "Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemias",
        "High Cholesterol",
        "Hypercholesterolemia",
        "Familial Hypercholesterolemia",
        "Atherosclerotic Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Obicetrapib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2530,
      "start_date": "2021-12-15",
      "completion_date": "2024-09-26",
      "has_results": true,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-10-04T09:06:25.056Z",
      "location_count": 69,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05142722"
    },
    {
      "nct_id": "NCT06250205",
      "title": "Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Obicetrapib",
          "type": "DRUG"
        },
        {
          "name": "Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)",
          "type": "DRUG"
        },
        {
          "name": "Drospirenone / Ethinyl Estradiol (COC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2024-02-05",
      "completion_date": "2024-04-26",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-04T09:06:25.056Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06250205"
    }
  ]
}